More Stories

Informist, Friday, Sept. 4, 2026

 

NEW DELHI – Pharmaceutical stocks are likely to be range-bound next week, with investors expected to remain selective amid mixed prospects across segments, analysts said. While differentiated and specialty products offer growth opportunities, weakness in some large-cap names and near-term technical pressure could limit a rise. 

 

The Nifty Pharma index ended at 26,478.10 points Friday, down 1.9% this week. The index is expected to trade in a range of 26000–26700 points next week, said Jatin Gedia, vice-president and technical research analyst at Teji Mandi. He expects Granules India to remain positive, while Cipla looks weak on technical charts.

 

"Indian pharma remained relatively resilient this week, with the focus increasingly shifting towards companies with differentiated products and higher barriers to entry," Niharika Agarwal, research analyst at Nirmal Bang Institutional Equities, said. Domestic formulations continue to provide a steady earnings base, particularly in chronic therapies, while US generics remain a mixed bag due to pricing pressure and launch volatility, Agarwal said.

 

Cipla's partnership with Qilu for QL2107, a Keytruda biosimilar, provides a capital-light route to build its US biologics portfolio, although the launch will face competition from peers such as Dr. Reddy's Laboratories and Zydus Lifesciences, she said. Gland Pharma could become interesting once selling pressure from Fosun's stake sale eases, provided its European contract development and manufacturing organisation integration and US Food and Drug Administration compliance remain on track, Agarwal said. She termed the stake sale largely a "shareholding-related overhang rather than a change in fundamentals".

 

Cohance Lifesciences is strengthening its position in antibody-drug conjugates through investments in NJ Bio and Aruka Bio, although the key question is how quickly these capabilities translate into meaningful customer and commercial revenue, she said. Wockhardt remains an interesting story as Zaynich moves from an approval-led narrative to US commercialisation, while Glenmark Pharmaceuticals continues to benefit from its specialty portfolio, anchored by Ryaltris, Agarwal said.

 

"Peptides, ADCs (antibody-drug conjugates), biologics, complex injectables, and specialty products are emerging as the more attractive areas within pharma, while plain-vanilla generics face fewer structural advantages," Agarwal said. She prefers Wockhardt, Gland Pharma, and Cohance for higher upside, albeit with higher execution risk, while Cipla and Glenmark offer a more balanced way to play the specialty theme.

 

TOP HEADLINES

* Cipla arm, Qilu Pharma in pact for licensing, supply of Pembrolizumab in US

* Cohance Life to invest $13 mln in arm NJ Bio, $5 mln in associate Aruka Bio

* Max Healthcare to infuse INR 878.7 mln into subsidiary Kalinga Hospital

* Max Health arm opens 400 bed new tower at Delhi hospital

* Give sample semaglutide tablets to Novo for testing, HC to Sun Pharma arm

* NCLT Mumbai approves merger of Docon Technologies with API Holdings

* Sun Pharma inks pact with US govt to extend MFN pricing to Medicaid schemes

* Cipla, SBP Group arm ink pact to develop, supply Rolditamig Deuderuxtecan

* Zydus Life completes phase-II(b) trial of Saroglitazar Mg successfully

* Aurobindo Pharma's US arm launches generic of asthma drug Advair Diskus

* US FDA tags Cipla arm's US unit as 'voluntary action indicated'

* PTI: Maharashtra FDA cancels sales licence of Cipla arm's Pune unit

* US FDA issues 3 observations to Aurobindo Pharma arm's mfg unit in Andhra

* NPPA fixes retail prices of 11 new drug formulations

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	26065.00	(-)0.40	26635.00	25525.00
Alkem Laboratories	5190.00	(-)3.10	5257.30	5096.30
Aurobindo Pharma	1653.10	0.50	1684.60	1606.80
Biocon	397.40	(-)3.30	408.20	390.80
Cipla	1385.00	(-)2.70	1410.10	1362.90
Divi's Laboratories	9100.00	(-)1.50	9325.30	8987.30
Dr Reddy's Laboratories	1151.00	(-)2.30	1172.10	1140.50
Gland Pharma	2932.40	1.50	3035.40	2799.60
GlaxoSmithKline Pharmaceuticals	2958.10	(-)4.80	2999.40	2904.80
Glenmark Pharmaceuticals	2437.20	(-)3.10	2472.90	2404.90
Granules India	848.30	1.40	875.20	825.20
Ipca Laboratories	1965.30	0.80	1984.30	1934.70
Laurus Labs	1840.00	(-)5.10	1885.60	1812.40
Lupin	2110.00	(-)2.80	2166.90	2072.10
Natco Pharma	828.65	(-)3.00	847.60	817.00
Pfizer	4609.70	(-)2.00	4710.40	4524.60
Sanofi India	3158.20	(-)0.70	3229.10	3115.50
Sun Pharmaceutical Industries	1899.00	(-)1.10	1926.10	1881.50
Torrent Pharmaceuticals	4857.00	(-)3.80	4991.70	4755.70
Zydus Lifesciences	1120.00	(-)6.00	1154.70	1102.70
Index	Levels
Nifty Pharma	26478.10	(-)1.90	26778.40	26311.20
Nifty 50	23897.70	(-)1.20	24043.00	23823.20
S&P BSE Sensex	76515.43	(-)1.00	77005.70	76270.30

 

End

 

Reported by Gunjan Rajput 

Edited by Shubhayan Bhattacharya

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.